The Federal Trade Commission is demanding internal communications, analysis and financial data related to Teva‘s contested patents for asthma and COPD inhalers, Dan Diamond of Washington Post reported earlier, citing confidential agency documents. Top Democrats have accused Teva and other companies of gaming the patent system and inflating patient costs by blocking generic competition, the paper added. The FTC last week sent a civil investigative demand, ordering Teva to provide internal communications, analysis and financial data related to the contested patents listed in the Orange Book, it adds. Teva has until July 24 to cooperate with the FTC’s demand. Shares of Teva are down 6c to $16.19 in midday trading.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA:
- Teva announces data from fourth interim analysis of PEARL study of AJOVY
- Teva price target raised to $23 from $19 at Jefferies
- Teva’s agreement with the ITA has no impact on 2024 financial outlook
- Teva reaches agreement with ITA, will pay $750M between 2024-2029
- Teva announces launch of authorized generic of Victoza in the U.S.
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue